Parameswaran Hari, MD, MRCP

Examining the Importance of the Institutional Perspectives in Cancer Webinars

April 2nd 2021

Jason Porter, MD, Subramanian Janakiraman, MD, Natalie S. Calendar, MD, Parameswaran Hari, MD, MRCP, and Kevin Kalinsky, MD, MS, discuss the importance of the Institutional Perspectives in Cancer webinars.

Dr. Hari on Key Treatment Considerations for Relapsed/Refractory Myeloma

March 9th 2021

Parameswaran Hari, MD, MRCP, shares key considerations for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Hari on the Role of Carfilzomib, Pomalidomide, and Dexamethasone in R/R Myeloma

February 17th 2021

Parameswaran Hari, MD, MRCP, discusses the efficacy of combination carfilzomib, pomalidomide, and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Dr. Hari on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

January 19th 2021

Parameswaran Hari, MD, MRCP, discusses treatment strategies for patients with relapsed/refractory multiple myeloma.

Dr. Hari on the Current and Potential Future Utility of Ixazomib Maintenance in Myeloma

June 16th 2020

Parameswaran Hari, MD, MRCP, discusses the current and potential future utility of ixazomib (Ninlaro) maintenance in multiple myeloma.

Dr. Hari on the Role of MRD in Multiple Myeloma

June 12th 2020

Parameswaran Hari, MD, MRCP, discusses the role of minimal residual disease in multiple myeloma.

Dr. Hari on Misconceptions Regarding Allogeneic Stem Cell Transplant in Multiple Myeloma

March 19th 2020

Parameswaran Hari, MD, MRCP, discusses misconceptions regarding allogeneic stem cell transplant in multiple myeloma.

Dr. Hari on CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

January 30th 2020

Parameswaran Hari, MD, MRCP, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Hari on Current State of Frontline Therapy in Myeloma

May 23rd 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the current state of frontline therapy in multiple myeloma.

Dr. Hari Discusses the Role of MRD in Myeloma

May 8th 2019

Parameswaran Hari, MD, MRCP, the Armand J. Quick/William F. Stapp Professor of Hematology, and the chief of the Division of Hematology/Oncology, Department of Medicine, at the Medical College of Wisconsin, discusses the role of minimal residual disease in myeloma.